May 25, 2020
Daiichi Sankyo said on May 22 that it has kicked off a PI clinical study of its GPR20-targetting antibody drug conjugate (ADC) DS-6157 in patients with advanced gastrointestinal stromal tumors (GISTs), with the first patient dosed. Designed by use of...read more